KALA BIO, INC. Restructuring and Related Cost, Number of Positions Eliminated
KALA BIO, INC. (KALA) had Restructuring and Related Cost, Number of Positions Eliminated of 19 employee as of 2025-09-29, per its 10-Q filed 2025-11-19.
Financial Statements › Notes › Restructuring and Related Cost, Positions Eliminated
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2025-11-19
- 2025-09-29: Restructuring and Related Cost, Number of Positions Eliminated 19.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2025-09-29 | 19.00 employee 10-Q · filed 2025-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |